Table 5 Distribution of observed minus expected cases between −1 and 10 years after biopsy according to GN diagnosis (%)
Renal Diagnosis | Number | Lung | Melanoma | Breast | Gynaecologic | Prostate | Renal | Bladder | Non-Hodgkin | Myeloma | Leukaemia | Unclassified | Skin | Typical cancers in the literature |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Minimal change | 27 | 11 | 6 | 13 | 10 | 7 | 41 | Renal, lung, colorectal, thymoma, Hodgkin’s | ||||||
Endocapillary | 6 | 37 | 11 | 24 | 14 | 15 | ||||||||
FSGS | 28 | 21 | 10 | 5 | 6 | 21 | 31 | Renal, thymoma | ||||||
Mesangio-proliferative | 53 | 12 | 9 | 12 | 21 | 45 | Renal, lung, unclassified | |||||||
Membranous | 51 | 17 | 6 | 10 | 5 | 21 | 36 | Renal, gastric, prostate, lung, unclassified | ||||||
Membrano-proliferative | 33 | 12 | 20 | 9 | 10 | 8 | 37 | Renal, lung, leukaemia, unclassified | ||||||
Proliferative | 9 | 6 | 7 | 8 | 10 | 24 | 45 | |||||||
Focal segmental proliferative | 29 | 9 | 23 | 11 | 51 | |||||||||
ANCA vasculitis | 26 | 6 | 10 | 5 | 11 | 7 | 61 | Skin, leukaemia, bladder | ||||||
Lupus (all) | 17 | 9 | 11 | 21 | 58 | Hodgkin, non-Hodgkin, myeloma, lung, leukaemia | ||||||||
Unclassified | 92 | 5 | 25 | 9 | 23 | 16 | 17 |